1st ILEP VIRTUAL SYMPOSIUM on CARDIOVASCULAR PREVENTION
1st ILEP (International Lipid Expert Panel) virtual symposium on cardiovascular prevention will be held on March 19th, 2022. Symposium Chairman: Prof. Maciej Banach Visit ILEP web site at: https://ilep.eu/ Program
16th LIPIDCLUB AND THERAPEUTIC APHERESIS
PICTURES OF THE EVENT October 7-8, 2021 – Verona 16th LIPID CLUB AND THERAPEUTIC APHERESIS Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques and Atherosclerosis Prevention Verona, October 7-8, 2021Camera di Commercio, Industria Artigianato e Agricoltura di Verona Corso Porta Nuova, 96 – 37122 Verona VR …
FCS Announcement
We are collecting anonymised information on patients with familial chylomicronaemia syndrome (FCS)/multifactorial chylomicronaemia syndrome (MCS) as a service evaluation & quality improvement project. The project aims to improve understanding of natural history of FCS and to validate the use of FCS scoring algorithm. The project is approved by Manchester University …
E-ISFA 2020 Announcement
3rd Congress of the European Group – International Society for Apheresis (E-ISFA) Dresden, March 19 to 21, 2020 Congress Topics Recent progress in lipoprotein apheresis Homozygous familial hypercholesterolemia Lipoprotein(a) Competition with drugs Plasma exchange Immunoadsorption – indications, results, future perspectives Experience with extracorporeal therapy in children and during pregnancy Apheresis …
LipidClub 2019
14th Lipid Club and Therapeutic Apheresis 2019 Udine, May 30-31 2019 ADVANCED COURSE ON CLINICAL LIPIDOLOGY, METABOLIC DISORDERS AND THERAPEUTIC APHERESIS FINAL PROGRAM
FAMILIÄRE HYPERCHOLESTERINÄMIE (FH)
Die Broschüre über familiäre Hypercholesterinämie von Österreichisches Akademisches Institut für Ernährungsmedizin (ÖAIE)
Cardiology Update Davos, Switzerland
Cardiology Update Davos, Switzerland 16-20 February 2019 Dear Colleagues It is my pleasure to announce the next Cardiology Update Course in Davos which belongs to the major meetings in the field of cardiology in Europe. As you know it is an Update Meeting endorsed by the ESC and a collaboration …
13th LipidClub & Therapeutic Apheresis – Interviews
Prof. Gerald Watts: Prof. Claudia Stefanutti Prof. Livia Pisciotta Prof. Widhalm
13th LipidClub and Therapeutic Apheresis – Streaming
Streaming – Part 1 Streaming – Part 2
13th LipidClub and Therapeutic Apheresis
13th LipidClub and Therapeutic Apheresis Program: LIPID-2018-final-program-10_04.pdf Registration form: Scheda LIPID 2018
Save the date! IAS 2018
23 Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis
2nd Congress of the European Group – International Society for Apheresis (E-ISFA)
12th Lipid Club and Therapeutic Apheresis
May 3-4 2017, Istituto Salesiano Sacro Cuore, Rome Final Program PRESENTATIONS
MightyMedic Workshop on Lipidology and Atherosclerosis – Genoa, Italy – 17 May 2017
LIPIDOLOGY AND ATHEROSCLEROSIS WORKSHOP European Society for Clinical Investigation May 17th, 2017 Preliminary program
HEART UK 31st Annual Medical & Scientific Conference
Cholesterol – A Problem Solved? HEART UK 31st Annual Medical & Scientific Conference Wednesday 5 – Friday 7 July 2017 Warwick Arts Centre, University of Warwick, Coventry CV4 7AL Conference website Register
The Global Gathering For Orphan Drugs
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY October, 4, 2016
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …
FH Europe 2016
[slideshow_deploy id=’1146′]
The role of microparticles in inflammation and transfusion: a concise review
Abstract Microparticles are small membrane-bound vesicles, found in body fluids including peripheral blood. Microparticles are an intrinsic part of blood labile products delivered to transfused patients and have active roles in inflammation. They are delimited by a lipid bilayer composed mainly of phospholipids, cholesterol, membrane-associated proteins, intracellular components such as metabolic enzymes, proteins-involved …
Implementing American Heart Association Pediatric and Adult Nutrition Guidelines
A Scientific Statement From the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research Read More
Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features
Studyquestion: Are differences in androgen levels among women with various forms of ovarian dysfunction associated with cardiometabolic abnormalities? summaryanswer: Androgen levels differed substantially between women with and without ovarian dysfunction, and increased androgen levels were associated with impaired cardiometabolic features in all women irrespective of their clinical condition. what is …